Inrebic (fedrantinib)

Numéro de dossier de l’APP: 21527
État des négociations:
Concluded with an LOI
Indication(s):
Treatment of splenomegaly and/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib
Promoteur/fabricant:
Celgene Inc.
Numéro de projet de l’ACMTS:
PC0205-000
Lettre-contrat de l’APP:
Conclusion du processus de négociation: